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The abba metallo b-lactamase (MBL) fold (MBLf) was ﬁrst observed in bacterial
enzymes that catalyze the hydrolysis of almost all b-lactam antibiotics, but is
now known to be widely distributed. The MBL core protein fold is present in
human enzymes with diverse biological roles, including cell detoxiﬁcation path-
ways and enabling resistance to clinically important anticancer medicines.
Human (h)MBLf enzymes can bind metals, including zinc and iron ions, and
catalyze a range of chemically interesting reactions, including both redox (e.g.,
ETHE1) and hydrolytic processes (e.g., Glyoxalase II, SNM1 nucleases, and
CPSF73). With a view to promoting basic research on MBLf enzymes and their
medicinal targeting, here we summarize current knowledge of the mechanisms
and roles of these important molecules.
Overview of the MBL Superfamily
The b-lactam antibiotics were discovered over 75 years ago, yet remain among the most
important medicines. One of the most important bacterial resistance mechanisms to b-lactam
antibiotics involves their hydrolysis, as catalyzed by two mechanistically distinct families: the
nucleophilic serine b-lactamases and the zinc ion-dependent MBLs (Class B b-lactamases)
[1,2].
In recent years, MBL-mediated antibiotic resistance, in particular to carbapenems (often anti-
biotics of last resort), has become widely disseminated. MBLs belonging to subclass B1, such
as the New Delhi metallo-b-lactamase 1 (NDM-1), are of widespread clinical signiﬁcance [3].
Following the successful development of serine b-lactamase inhibitors (Box 1), MBL inhibitors
are being developed [4], but none have yet been developed for clinical use.
The determination of crystal structures for prokaryotic b-lactam hydrolyzing MBLs (class B b-
lactamases) led to the discovery of a novel /bb/ protein fold and the ﬁnding that the MBLf is
widely distributed in biology, including in humans, where it supports diverse roles [5–7]. To
date, the MBL superfamily includes >34 000 predicted members of diverse function and metal
utilization (see [7–9] for recent detailed reviews). Most of the characterized and predicted MBLf
enzymes are hydrolases acting on nucleic acids and small molecules (including b-lactam
antibiotics), but they can also catalyze different types of reaction, including in redox chemistry,
such as during detoxiﬁcation of hydrogen sulﬁde [10]. In a notable parallel with the role of
bacterial MBLs in antibiotic resistance, some hMBLf enzymes (e.g., the DNA crosslink repair
enzymes SNM1A and B) enable resistance to anticancer drugs of major clinical relevance,
including mitomycin C and cisplatin [11]. Work on hMBLf enzymes is of fundamental
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enzymology interest because of the range of reactions catalyzed by a single protein fold [7–9]; it
is also of medicinal relevance because it may help both enable development of selective
inhibitors for the prokaryotic b-lactam-hydrolyzing MBLs and in the development of drugs to
overcome resistance to chemotherapeutic agents. In this review, we summarize current
knowledge of hMBLf proteins, with a view to promoting basic and medicinal research on
these important molecules.
Overview of hMBLf Enzymes
Structurally informed sequence analyses reveal (at least) 18 hMBLf proteins, all of which contain
some of the conserved active site ‘motifs’ present in b-lactam antibiotic-hydrolyzing prokaryotic
MBLs. In hMBLf enzymes, there are ﬁve identiﬁed active site motifs: (i) H84; (ii) H116XH118XD120H121;
(iii) H196; (iv) D221; and (v) H263, with the ﬁrst three being best conserved [7,8]. Human motif (i) (H84) is
not present in the b-lactam antibiotic-hydrolyzing prokaryotic MBLs and motif (iv) (D221) replaces
the prokaryotic C221 motif. Phylogenetic analyses (Figure 1) cluster hMBLf proteins into three
groups or subfamilies. Group 1 comprises glyoxalase II family-related enzymes, Group 2 com-
prises enzymes involved in nucleic acid modiﬁcations, including some linked to anticancer drug
resistance, and Group 3 comprises hMBLf proteins with more diverse functions. For a general
overview of hMBLf enzyme function, localization, and metal utilization, see Table 1. Here, we
describe work on these subfamilies, beginning with the glyoxalase II-related enzymes, some of
which act on small molecules in a manner related to b-lactam chemistry.
Box 1. b-Lactam Antibiotic Resistance and b-Lactam Antibiotic Hydrolyzing MBLs
Beginning with the penicillins, successive generations of classes of b-lactam antibiotic, including the cephalosporins and
carbapenems, were developed. However, all b-lactam antibiotic classes are vulnerable to resistance mechanisms,
including efﬂux pumps, target mutations, and, probably most importantly to date, their inactivation by b-lactamases,
which hydrolyze them into inactive b-amino acids [98–101]. In mechanistic terms, the b-lactamases are divided into those
using a nucleophilic serine residue (serine b-lactamases, SBLs; classes A, penicillinases; C, cephalosporinases; and D,
oxacillinases) and those using zinc ions (MBLs; class B) in catalysis [1,2].
Pioneering work led to the discovery of the clinically useful b-lactamase inhibitors clavulanic acid, sulbactam, and
tazobactam [102]. Remarkably, these compounds are themselves b-lactams; although they are insufﬁciently active to be
used as antibiotics, in combination therapies they are effective at protecting for example, penicillins from penicillinase-
mediated hydrolysis. A new b-lactamase inhibitor, avibactam, is not a b-lactam but does have a reactive carbonyl group;
it has been recently approved for use in combination therapies with penicillinases as an inhibitor of class A, C, and some D
b-lactamases [4]. The MBLs are concerning because they catalyze the hydrolysis of almost all b-lactam antibiotics and
serine b-lactamase inhibitors.
The classical prokaryotic MBLs catalyze b-lactam hydrolysis via a mechanism involving zinc-mediated b-lactam and
water activation (Figure IA). They can use either one or two active site-bound zinc ions, although the latter is more
common; in isolated form, they can also use transition metal ions other than zinc [103]. MBLs are classiﬁed into three
subfamilies (B1, B2, and B3 MBLs) based on substrate selectivity and/or sequence/structure-based homologies [8]; all
have the characteristic /bb/ core fold, as ﬁrst revealed in a MBL II structure from Bacillus cereus in 1995 [5]. Distinctive
active site elements, including four highly, but not universally, conserved zinc ion-binding motifs occur in the MBLs: (i)
H116XH118XD120 (an additional residue His121 is only present in subclass B3); (ii) H196; (iii) C221; and (iv) H263 (Figure IB).
Note that wherever possible, we use the MBL ‘BBL’ numbering system [104]. The structural work revealed that the MBLf
is widespread. To date, >34 000 predicted MBLf proteins have been identiﬁed [3,9,105,106]; while of these many are
‘classical’ antibiotic resistance MBLs (<1000), many are not [9,103,107].
Although gaps remain in our knowledge, a combination of crystallographic, modeling, and solution studies using kinetics
and spectroscopic methods is enabling a detailed mechanistic understanding of the prokaryotic MBLs. The zinc ions
have central roles in catalysis, not only in activating both the ‘hydrolytic’ water and the b-lactam carbonyl, but also in
substrate binding, including via the carboxylate present in most b-lactam antibiotics (Figure IA). Notably, the b-lactam
antibiotic aztreonam does not contain such a carboxylate and is not an MBL substrate [108], illustrating that is possible to
obtain selectivity in binding to MBLs, even with related compounds. Various MBL inhibitors have been reported,
principally in the academic literature, and some patents have been ﬁled [109,110]. Perhaps the best-characterized
MBL inhibitors are thiols, which displace the ‘hydrolytic’ water that bridges the two zinc ions that are found in clinically
relevant MBLs [18]. As yet, no MBL inhibitors have progressed to the clinic; however, the available evidence suggests that
they will be viable targets, at least in term of achieving efﬁcacy.
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Group 1 hMBLf Enzymes: The Glyoxalase II Subfamily
The Glyoxalase II subfamily of hMBLf enzymes comprises seven members: hydroxyacylgluta-
thione hydrolase (HAGH) or Glyoxalase II itself; hydroxyacylglutathione hydrolase-like protein
(HAGHL); ethylmalonic encephalopathy protein 1 (ETHE1); MBL domain-containing protein 1
(MBLAC1); MBL domain-containing protein 2 (MBLAC2); beta-lactamase-like protein 2
(LACTB2); and paroxysmal nonkinesiogenic dyskinesia protein (PNKD) (Table 1). Of the Glyox-
alase II hMBLf proteins, biochemical functions have been assigned for two (HAGH and ETHE1).
HAGH
HAGH catalyzes a key step in the detoxiﬁcation of reactive and toxic 2-oxoaldehydes, including
methylglyoxal [12]. 2-Oxoaldehydes react with DNA and proteins, resulting in aberrant
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Figure I. The Reaction Catalyzed by ‘Classical’ Bacterial Metallo b-Lactamases (MBL) Mediates Resis-
tance to b-Lactam Antibiotics. (A) Outline mechanism for the MBL hydrolysis reaction for subclass B1 enzymes
exempliﬁed with a cephalosporin antibiotic (in green). (B) View from a crystal structure of NDM-1 b-lactamase (subclass
B1) showing the overall fold of a bacterial MBL [Protein Data Bank (PDB) ID: 4RL0] and of its active site in complex with a
product derived from cephalosporin hydrolysis (in green). The MBL domain is in blue (b-sheets) and cyan (/-helices). N-
and C-terminal residues are in red. Zinc ions are in pink; water molecules are in red.
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postoligomerization modiﬁcations, which are associated with aging by causing DNA instability
and alteration of protein function [13].
The well-characterized glyoxalase system converts the toxic 2-oxoaldehydes to less-reactive
metabolites [13] and comprises two key enzymes: Glyoxalase I and HAGH [13]. Glyoxalase I,
which is not an MBLf protein, catalyzes the ﬁrst step; that is isomerization of a nonenzymatically
formed hemithioacetal adduct of the ubiquitous reducing agent glutathione and the toxic 2-
oxoaldehyde, to give a (S)-2-hydroxyacylglutathione thioester [14]. HAGH then catalyzes hydro-
lysis of the thioester to give a 2-hydroxycarboxylate product (e.g., lactate from methylglyoxal)
and regenerate glutathione (Figure 2A) [13].
Following the determination of a crystal structure for HAGH [Protein Data Bank (PDB) ID:1XM8]
from Arabidopsis thaliana, which revealed a di-zinc binding site [15], human HAGH structures
have been reported, including in complex with glutathione and the substrate analog S-(N-
hydroxy-N-bromophenylcarbamoyl)glutathione (PDB ID: 1QH3/5); this is one of the few MBL
structures providing detailed insights into substrate binding [16] (Figure 3A). As with other MBLf
superfamily members, HAGH can use metal ions other than zinc, including iron and manganese
ions [17]. Of the characterized hMBLf proteins, the HAGH reaction is perhaps the most closely
related to that of classical MBLs. The proposed HAGH mechanism involves nucleophilic attack
of water onto the substrate carbonyl to give a negatively charged tetrahedral intermediate that is
stabilized by a zinc ion, followed by C–S bond cleavage (Figure 4A). In this regard, it is notable
that, in solution, the proposed rate-limiting step in HAGH catalysis and, at least in some cases of
b-lactam hydrolysis, is breakdown of the tetrahedral intermediate, whereas in acyclic amide
hydrolysis, it is (normally) formation of the tetrahedral intermediate. Interestingly, some b-lactam
antibiotics hydrolyzing MBLs can catalyze thioester hydrolysis in a mechanism related to that of
HAGH [9], and thiols are an established class of MBL inhibitors [18,19].
ETHE1
ETHE1 has a key role in the mitochondrial metabolism of the toxic (and smelly) small molecule
H2S. In mitochondria, ETHE1 catalyzes the oxygen-dependent conversion of the persulﬁde
(GSSH) formed from glutathione and H2S to give glutathione and persulﬁte [10] (Figure 2A).
Mutations in the ETHE1 gene correlate with the autosomal recessive metabolic disease ethyl-
malonic encephalopathy (EE), which leads to death in infancy [20–22]. To date, 16 clinically
observed mutations have been identiﬁed in ETHE1, at least some of which are likely inactivating.
Substitutions at the conserved Arg163, located on a loop in close proximity to the active site, are
proposed to cause reduced protein stability and alteration of the redox potential of the iron
center [23]. However, some missense mutations occurring at highly conserved residues lead to
normal or reduced levels of active ETHE1 [10,20,24,25].
ETHE1 is overexpressed in hepatocellular carcinoma cells and is proposed to abrogate apo-
ptosis mediated by the transcription factor p53, thereby enhancing cancer progression [26,27].
Two possible mechanisms have been proposed for this process. ETHE1 is proposed to act as a
nuclear-cytoplasmic shuttling protein that binds the nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-kB) protein RelA/p65 in the nucleus and promotes its transport to the
cytoplasm. Given that the nuclear localization of NF-kB is essential in p53-mediated apoptosis,
the ETHE1-dependent sequestration of RelA/p65 in the cytoplasm results in failure of p53-
mediated cell death [26]. Alternatively, it is proposed that ETHE1 may reduce p53-regulated
transcription of proapoptotic genes by interacting with histone deacetylase 1 (HDAC1) and
thereby promotes p53 deacetylation [27]. Given the roles of ETHE1 in thiol metabolism and the
role of metal ions in both HDAC and hMBLf catalysis, it is notable that HDAC inhibitors are often
metal chelators, including appropriately functionalized thiols and hydroxamic acids. These
classes of HDAC inhibitor are known classes of ‘classical’ MBL inhibitor [28]. It is possible that
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Figure 1. Phylogeny and Domain Architecture of Human Metallo b-Lactamase Fold (hMBLf) Enzymes. (A)
Phylogenetic tree representation of the hMBLf superfamily generated using the Clustal Omega multisequence alignment
tool [111]. (B) Domain architecture of hMBLf enzymes. Note that the DRMBL motif, if present, is shown as a small yellow
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the biological activities of such inhibitors, including effects on cell proliferation, arise from
inhibition of hMBLf proteins (including ETHE1) in addition to HDACs.
From a mechanistic perspective, ETHE1 is remarkable. Biochemical and structural studies reveal
that it binds a single Fe (III) ion, instead of Zn (II), into its active site [10,29]. The human ETHE1
structure (PDB ID: 4CHL) [30] is closely related to that of ETHE1 from A. thaliana and reveals a
dimer with a single iron ion at each active site [30] (Figure 3A). Interestingly, in both the A. thaliana
and human ETHE1 structures, an oxidized cysteine residue is present close to the active site,
although the role of this modiﬁcation in unknown [29,30]. In a manner closely reminiscent of the
nonheme iron oxygenases of the 2-oxoglutarate oxygenase and other superfamilies, ETHE1
uses a 2-His-carboxylate site motif to complex its nonheme iron. The proposed ETHE1
mechanism is related, at least in some aspects, to that of the key enzyme in penicillin biosyn-
thesis [i.e., isopenicillin N synthase (IPNS) [31]], and involves initial complexation of the GSSH
thiol and cysteinyl-glycine amide nitrogen to the iron followed by binding of O2 and oxidation of
ligated sulfur or disulﬁde [10,30] (Figure 4B). Further work is required to characterize the
proposed intermediates in ETHE1 catalysis.
PNKD
PNKD exists in four different isoforms (due to alternate splicing), of which isoforms 1, 3, and 4
contain an MBLf domain, whereas isoform 2 does not [32]. The biochemical role and mechanism of
PNKDs are unknown. The PNKD MBLf domain has high sequence similarity with HAGH, and
PNKD is proposed as a Glyoxalase II-type enzyme [33]. Mutations of the PNKD gene correlate with
paroxysmal nonkinesigenic dyskinesia or Dystonia type 8 (DYT8), which is characterized by
dystonia, chorea, and athetosis (i.e., involuntary muscle contractions) [33–35]. The observation
of dysfunction in dopamine signaling (i.e., increased dopamine turnover) in the basal ganglia of
PNKD-1-knockout mice suggests that the dopamine pathway is involved in paroxysmal non-
kinesigenic dyskinesia [33,36]. In support of this, mutant PNKD-expressing mice display alter-
ations in exocytosis, suggesting that PNKD is involved in modulation of neurotransmitter release at
the nigrostriatal dopaminergic terminals [37]. PNKD is present in muscle tissues including skeletal
muscle and myocardial myoﬁbrils, where it interacts with sarcomeric proteins, indicating a role for it
as a myoﬁbrillogenesis regulator [38–40]. PNKD2 stimulates ﬁber formation and, indirectly,
activates the focal adhesion kinase/(Ser/Thr) kinase (FAK/Akt) signaling pathway to promote cell
migration and proliferation [41]. PNKD2 is overexpressed in some cancer cells (e.g., ovarian) and is
proposed to be involved in tumor cell proliferation, migration, and adhesion [42]. Although the
biochemical roles of PNKD have not yet been identiﬁed, collectively these studies suggest that
PNKD is involved in multiple cellular pathways, and its malfunction has pleiotropic consequences.
The other Glyoxalase II hMBLf subfamily proteins are of unassigned function. Sequence
analyses suggest that MBLAC1/2, HAGHL. and LACTB2 bind two metal ions [as supported
by crystallographic analyses for LACTB2 (PDB ID: 4AD9)] and may be hydrolases (Figure 3A).
Group 1 hMBLf Enzymes: Summary
Of the seven members of the glyoxalase II subfamily, biochemical functions have been assigned
only for two (HAGH and ETHE1). However, the established and apparently physiologically
block [112]. Abbreviations: CMAHP, CMP-N-acetylneuraminic acid hydroxylase pseudogene; CPSF100, cleavage and
polyadenylation speciﬁcity factor 100; CPSF73, cleavage and polyadenylation speciﬁcity factor 73; CPSF73L, cleavage and
polyadenylation speciﬁcity factor 73 like; DCR1A (SNM1A), DNA crosslink repair 1A; DCR1B (SNM1B/Apollo), DNA
crosslink repair 1B; DCR1C (SNM1C/Artemis), DNA crosslink repair 1C; DRMBL, DNA repair metallo b lactamase; ELAC1
and 2, zinc phosphodiesterase ELAC protein 1 and 2; ETHE1, ethylmalonic encephalopathy protein 1; HAGH, hydro-
xyacylglutathione hydrolase or Glyoxalase II; HAGHL, hydroxyacylglutathione hydrolase or Glyoxalase II like; INTS9,
integrator complex subunit 9; LACTB2, b-lactamase-like protein 2; MBLAC1 and 2, MBL domain-containing protein 1
and 2; NAPE-PLD, N-acyl-phosphatidylethanolamine-hydrolyzing Phospholipase D; PNKD, paroxysmal nonkinesiogenic
dyskinesia protein; RNAse Z, ribonuclease Z; b-CASP, CPSF-Artemis-SNM1-Pso2.
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Table 1. Overview of Reported Studies on hMBLf Enzyme Functions, Localizations, and Metal Utilization
hMBLf Proteins
(PDB ID)
hMBLf
Protein
Group
Gene ID; EC;
Chromosome
Location
Assigned Subcellular Localization Function/Proposed Function Reported
Metal
Content
Linked Diseases Refs
HAGH (1XM8) 1 3029; 3.1.2.6; 16p13.3 C, Ma Glutathione biosynthetic process. di-Zn (II) None assigned [31,113]
HAGHL 1 84264; 3.1.2.-; 16p13.3 N/D N/D di-Zn (II)b None assigned
ETHE1 (4CHL) 1 23474; 1.13.11.18;
19q13.31
C, M, N Glutathione metabolic process.
Hydrogen sulﬁde metabolic
process
Fe (II) Ethylmalonic encephalopathy (EE) [14,34,
40,44]
LACTB2 (4AD9) 1 51110; 3.-.-.-; 8q13.3 M (by Compara), C (by PSORT II) N/D di-Zn (II)b None assigned
MBLAC1/2 1 255374/153364; 3.-.-.-;
7q22.1/5q14.3
N/D N/D di-Zn (II)b None assigned
PNKD 1 25953; 3.-.-.-; 2q35 I 1: ME; I 2: C (http://www.uniprot.
org/locations/SL-0086)
N/D Zn (II) Dystonia type 8 (DYT8) [47,54]
SNM1A (4B87) 2 9937; N/A; 10q25.1 N Cell cycle, DNA damage/ repair Zn (II) Mutations: impaired nuclear focus
formation, reduced interaction with
PIAS and increased sensitivity to
cisplatin
[15,61,
62]
SNM1B (5AHO) 2 64858; 3.1.-.-; 1p13.2 CH, C, CY, N; T DNA damage/repair di-Zn (II)b Hoyeraal–Hreidarsson Syndrome [61,114,
116]
SNM1C 2 64421; 3.1.-.-; 10p13 N Adaptive immunity; DNA
damage, recombination, repair
N/D Severe combined immunodeﬁciency
autosomal recessive T cell-negative/
B cell-negative/NK cell-positive with
sensitivity to ionizing radiation
(RSSCID), Severe combined
immunodeﬁciency Athabaskan
type (SCIDA), Omenn syndrome
(OS)
[71,115,
117,118]
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Table 1. (continued)
hMBLf Proteins
(PDB ID)
hMBLf
Protein
Group
Gene ID; EC;
Chromosome
Location
Assigned Subcellular Localization Function/Proposed Function Reported
Metal
Content
Linked Diseases Refs
ELAC1 (3ZWF) 2 55520; 3.1.26.11; 18q21 N tRNA processing di-Zn (II)b None assigned [82]
ELAC2 2 60528; 3.1.26.11;
17p11.2
M, N tRNA processing di-Zn (II) Prostate cancer, hereditary, 2
(HPC2)
[76,79,
84]
CPSF73 (2I7T) 2 51692; 3.1.27.-; 2p25.1 N mRNA processing di-Zn (II) None assigned [88,89]
CPSF73L 2 54973; 3.1.27.-; 1p36.33 N, C pre-snRNA processing N/D None assigned [94]
CPSF100 2 53981; N/A; 14q31.1 N mRNA processing c None assigned [90]
INTS9 2 55756; N/A; 8p21.1 N/D snRNA processing N/D None assigned
NAPE-PLD (4QN9) 3 222236; 3.1.4.54; 7q22.1 ME Lipid/Phospholipid degradation,
metabolism
di-Zn (II) None assigned [97,101]
CMAHP 3 8418; N/A; 6p21.32 C (http://www.ebi.ac.uk/QuickGO/
GTerm?id=GO:0005737)
N/A d N/A [108]
aAbbreviations: C, cytoplasm; CH, Chromosome; CY, cytoskeleton; M, mitochondria; ME, membrane; N, nucleus; PDB, protein data bank; snRNA, small nuclear RNA; T, telomere; N/D, not determined.
bProposed di-Zn (II) ions observed in the active site inferred by sequence similarity with reported MBL crystal structures.
cLikely a catalytically inactive hMBLf (no metal ion binding observed in the modiﬁed ‘active sites’, by crystallographic analyses of the yeast CPSF100 ortholog).
dNo metal due to the loss of MBL domain in the assigned pseudogene.
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essential roles of HAGH and ETHE1 in detoxiﬁcation and pleiotropic aspects of biology, along
with the disease-associated links of PNKD, imply that the Glyoxalase II subfamily of hMBLf
enzymes likely has more central roles in metabolism than was previously perceived.
Group 2 hMBLf Enzymes: The DNA/RNA Interacting hMBLf Subfamily
The DNA/RNA interacting hMBLf subfamily is the largest hMBLf subfamily, comprising nine
proteins that are mostly nucleases, and are involved in DNA repair and somatic recombination in
the immune system (SNM1 A, B, and C), and RNA processing (ELAC1-2 and the CPSFs) [43]
(Figure 2B). Six of them (SNM1 A, B, C, CPSF73, CPSF73-like, and CPSF100) also contain a
discrete b-CPSF-Artemis-SNM1-Pso2 (b-CASP) domain, which along with the MBLf domain is
involved in nucleic acid binding [44,45]. The SNM1 enzymes (SNM1 A, B, and C) are orthologs of
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Figure 2. Known Reactions Catalyzed by Human Metallo b-Lactamase Fold (hMBLf) Enzymes (and Cytidine
Monophospho-N-Acetylneuraminic Acid Hydroxylase). (A) Group 1, glyoxalase II, and human ethylmalonic ence-
phalopathy protein 1 (hETHE1); (B) Group 2: DNA crosslink repair 1 (DCR1 or SNM1A, B, and C) enzymes; (C) Group 3: N-
acyl-phosphatidylethanolamine-hydrolyzing phospholipase D (NAPE-PLD) and an enzyme present in most if not all
mammals except humans, cytidine monophospho-N-acetylneuraminic acid hydroxylase (CMAH). Substrate atoms directly
involved in enzyme catalysis are in red. Note that not all hMBLs have assigned functions.
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noncatalytic domains) enzyme–substrate and/or product structures reported for nonclassical MBLs; product complex
structures are reported for classical MBLs [114].
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the budding yeast enzyme Pso2, and have been found to have important roles in eukaryotic DNA
damage repair [46,47]. In an interesting parallel with the role of prokaryotic MBLs in resistance to
b-lactam antibiotics, the SNM1 nucleases are involved in resistance to antitumor drugs.
DNA Crosslink Repair 1A and 1B Enzymes (DCR1A and 1B or SNM1A and 1B)
DNA crosslink repair 1A (SNM1A or DCR1A) and DNA crosslink repair 1B (SNM1B, DCR1B,
or Apollo) are 50-30 exonucleases that are activated on DNA damage. SNM1A/B are important
in interstrand crosslink (ICL) repair; in particular, SNM1A has a striking ability to resect past
site-speciﬁc crosslinks in vitro [48]. Cells depleted in SNM1A/B show increases in sensitivity to
ICL-inducing agents, such as cisplatin and mitomycin C [49]. Mutations of the SNM1A and
SNM1B MBLf domains cause loss of nuclease activity, revealing the crucial role of the MBLf
domain in repair [49,50]. Cells depleted of SNM1A accumulate double-strand (ds) breaks
(DSB) as a consequence of replication fork breakage. These observations indicate a role for
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SNM1A in the predominant, replication-coupled, ICL repair pathway. In support of this, in
mammalian cells, SNM1A promotes G1 cell cycle checkpoint arrest after exposure to ionizing
radiation [51,52].
SNM1B has an established role in telomere maintenance via interaction with the telomere-
associated factor (TRF2) [50]. SNM1B is involved in the generation of 30-overhang structures at
telomeres, protecting them from deleterious repair by nonhomologous end-joining (NHEJ) [53].
Similarly to SNM1A, depletion of SNM1B sensitizes cells to ICLs as well as to other genotoxins,
such as ionizing radiation and cisplatin [54–56].
DNA Crosslink Repair 1C (DCR1C, SNM1C, or Artemis)
SNM1C has a key role in one of the major pathways for repair of DSB in mammalian cells: the
NHEJ pathway [47]. SNM1C is also involved in antibody and T cell diversiﬁcation as a conse-
quence of its role in V(D)J recombination, a specialized somatic recombination process that is
essential for adaptive immunity [57]. SNM1C is a 50-30 exonuclease acting on both single-strand
(ss) and ds DNA and, uniquely within the DNAase MBLf family, is also an endonuclease that acts
on DNA hairpin structures generated during V(D)J recombination and on DNA overhangs during
NHEJ repair of ds breaks. The endonuclease activity of SNM1C is promoted by its phosphor-
ylation and complexation with DNA-dependent protein kinases [58,59]. Mutations of the SNM1C
MBLf domain correlate with radiosensitive severe combined immunodeﬁciency syndrome (RS-
SCID), likely due to impaired V(D)J recombination [57,59] and defects in repair of ionizing-
radiation-induced ds breaks. The C-terminal region of SNM1C directly interacts with the binding
domain of DNA Ligase IV, a unique mammalian ligase involved in the ﬁnal step of ds break repair
by NHEJ [60]. Inhibition of the SNM1C/Ligase IV complex formation is of medicinal interest,
because decreasing the efﬁciency of NHEJ repair in tumors might synergize with chemothera-
peutic agents and radiotherapy [60]. SNM1C may also have a role in cell cycle regulation via
direct interaction with the Cul4A-DDB1 E3 ubiquitin ligase complex, which is required for the
degradation of the cyclin-dependent kinase protein inhibitor p27 during the transition from G1 to
S phase [61].
ELAC 1 and 2 Proteins (ELAC1/2)
ELAC1/2 are nucleases that mediate 30-tRNA processing; both belong to the RNAse Z family and
contain two active site zinc ions [62]. Human ELAC1 is signiﬁcantly smaller than ELAC2 (363 versus
826 residues), and is similar to the C-terminal MBL domain-containing region of ELAC2; thus,
ELAC1 is likely to have evolved as a consequence of gene duplication [63]. ELAC2 displays activity
as a 30-end tRNA-processing nuclease involved in the maturation of mitochondrial (mt) tRNA
[64,65]. Mutations in the ELAC2 gene correlate with accumulation of unprocessed (mt) tRNAs,
leading to impaired mitochondrial translation, which is associated with hypertrophic cardiomyop-
athy, an often lethal inborn pathology [66]. Similar to ELAC2, ELAC1 has 30-tRNA-processing
activity and appears to have endoribonuclease activity on unstructured RNA [67]. Although they
have similar biochemical functions, the ELAC proteins have different subcellular localizations.
ELAC1 localizes in the cytoplasm, whereas ELAC2 localizes in both the nucleus and mitochondria
[68]. The cytoplasmic localization of ELAC1 suggests that it is responsible for degradation of
unstructured RNA [68]. By contrast, ELAC2 reportedly interacts with the -tubulin complex in the
centrosome during cell division, suggesting a possible role as a cell cycle regulator. Such a role
could explain the correlation between mutations in ELAC2 and tumor onset, and other links
between polymorphism of ELAC2 and prostate cancer development [69–72].
The Cleavage and Polyadenylation Speciﬁcity Factor hMBLf Proteins
CPSF73 and CPSF100
CPSF73 and CPSF100 are members of the multicomponent cleavage and polyadenylation
speciﬁcity factor (CPSF) complex that includes nuclease activities important in RNA processing
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[73]. The endonuclease activity of CPSF73 is a key factor in transcription termination and in
subsequent processing of 30-end polyadenylated mRNA precursors [74]. Additionally, CPSF73
has 50-30 exonuclease activity and is involved in histone 30-end pre-mRNA processing [75]
(Figure 3B). By contrast, CPSF100 does not have RNA processing activity, likely due to a lack of
key ‘catalytic’ residues within the second motif (HXHXDH) of its MBLf domain (the motifs were
described above) [7,8]. Indeed, a crystal structure of yeast CPSF100 does not reveal active site-
bound metal ions [74]. Comparison of crystal structures for human CPSF73 and the yeast
CPSF100 reveals highly similar overall folds despite substantially different sequences [74].
Notably, human CPSF100 can exist as a heterodimer with CPSF73; this interaction is proposed
to enable the complex to recruit speciﬁc pre-mRNAs for processing [73,76]. The precise
function, if any, of the apparently catalytically inactive CPSF100 MBL domain is unknown; it
is likely that the overall MBL/b-CASP architecture is necessary for the interaction with CPSF73
and perhaps other components of the CPSF complex (including RNA) to form active the
multiprotein complexes required for mRNA processing [76,77].
Integrator Complex Subunit 9 (INTS9) and CPSF73L (INTS11)
INTS9 and CPSF73L are hMBLf proteins that are part of the integrator complex, which binds
RNA Polymerase II and regulates the expression of target genes. The integrator complex
hydrolyzes small nuclear (sn) RNA sequences as part of their transcription termination-linked
processing. Recently, the integrator complex was reported to be fundamental in histone mRNA
processing [78,79]. After heterodimerization with INTS9, INTS11 manifests the endonuclease
activity necessary for the maturation of snRNA by removal of the 30 ends of pre-snRNA in a
manner that resembles the CPSF73–CPSF100 interaction; that is, INTS9 is catalytically inactive
and forms a heterodimer with active INTS11 that then shows endonucleolytic activity [80,81]. At
present, there is little structural or biochemical information on integrator complexes; such studies
will be vital to understanding how snRNA and histone mRNA bind to the integrator complex.
Structural Studies on hMBLf Nucleases
At present, crystal structures of four of the nuclease subfamily of hMBLf proteins have been
reported, for SNM1A, SNM1B, CPSF73, and ELAC1; all of which bind one or two zinc ions in
their active site (Figure 3B). Crystallographic analyses show a single zinc ion in the SNM1A active
site (PDB ID: 4B87), but two zinc ions in the SNM1B active site (PDB ID: 5AHO), as observed for
ELAC1 (PDB: 3ZWF) and CPSF73 (PDB ID: 2I7T) [74]. More detailed biochemical analyses are
required to deﬁne the biologically relevant metal usages. The CPSF73 and SNM1A/B structures
display high overall similarity, in part because they have both MBL and b-CASP domains
(Figure 3B); in each case, both domains are required for catalysis, consistent with the similarity
in the reactions catalyzed by each (Figure 2B). By contrast, in ELAC1, the /bb/ core MBLf
structure represents the entire ELAC1 protein, consistent with the different reactions catalyzed
by ELAC1 [67]. Despite the emerging structural information, the mechanistic details of the hMBLf
nucleases remain to be determined. By analogy with the MBLs, an outline mechanism of action
for the SNM1 enzymes is shown in Figure 4C: a zinc ion-activated water mediates nucleophilic
attack on the phosphate group, which is also activated and/or bound to a zinc ion.
Group 2 hMBLf Enzymes: Summary
Group 2 hMBLf proteins comprise nine enzymes involved in DNA repair pathways (SNM1
enzymes) and processing of different types of RNA (CPSF enzymes, ELAC1, and ELAC2). Six of
these are characterized by the presence of an additional b-CASP domain, which is required for
nucleic acid binding (SNM1 enzymes, CPSF73, CPSF73L, and CPSF100) and nuclease
catalysis. Crystallographic studies reveal one or two zinc ions at the active sites of SNM1A,
SNM1B, CPSF73, and ELAC1, suggesting possible variations in a related nuclease mechanism.
Since no detailed mechanistic studies have been carried out for an MBLf nuclease, further work
in this ﬁeld will be of value, including with respect to the development of selective inhibitors; these
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are of particular interest for the SNM1 enzymes to extend the use of ICLs producing anticancer
drugs. Although all the enzymes in this subfamily are nucleases, they have strikingly different
selectivities for their nucleic acid substrates; to what extent these arise from direct enzyme–
substrate interactions, and/or from interactions within the multicomponent and dynamic com-
plexes in which the enzymes operate in cells, is not resolved.
Group 3: Other hMBLf Enzymes: NAPE-PLD and CMAH
N-Acyl-Phosphatidylethanolamine-Hydrolyzing Phospholipase D (NAPE-PLD)
NAPE-PLD is widely expressed, including in the brain [82], and has an important role in the
conversion of metabolic lipids into signaling molecules, such as the neurotransmitter N-
arachidonoylethanolamine (anandamide), which acts on cannabinoid receptors. In the endo-
cannabinoid pathway, NAPE-PLD catalyzes hydrolysis of NAPEs to form anandamide (AEA)
and other N-acylethanolamines (Figure 2C) [82,83]. Among N-acylethanolamines, N-palmi-
toylethanolamine has attracted attention due to its peroxisome proliferator-activated receptor
(PPAR/)-mediated anti-inﬂammatory activity [84]; thus, NAPE-PLD could have a role in the
anti-inﬂammatory response. NAPE-PLD is important for fertility because it is a major regulator
of AEA in the uterus during the initial stages of pregnancy and high levels of AEA are
associated with early pregnancy failure [85]. Recently, targeted deletion of NAPE-PLD in
adipocytes has been reported to induce obesity, glucose intolerance, adipose tissue inﬂam-
mation, and altered lipid metabolism [86]. The results suggest that targeting signaling lipids
derived by NAPE-PLD catalysis may be useful for the treatment of obesity and metabolic
syndrome.
A human NAPE-PLD structure has been reported (PDB ID: 4QN9) (Figure 3C), which reveals a
dimer and a di-zinc active site where residues belonging to the conserved hMBLf motifs
coordinate the metals [87]. NAPE-PLD binds two zinc ions, but it is also active with different
divalent metal ions, including Mg (II), Ca (II), Co (II), Mn (II), and Ba (II) [83]. Recently, desketor-
aloxifene analogs have been identiﬁed as broad-spectrum inhibitors of different phospholipase D
enzymes, including hNAPE-PLD; these ﬁndings may help to better investigate the physiological
roles of NAPE-PLD and eventually lead to useful clinical applications [88].
Cytidine Monophospho-N-Acetylneuraminic Acid Hydroxylase
Sialic acids occur at the termini of sugar chains on the surface-exposed portion of plasma
membrane proteins and have important roles in ligand–receptor, cell–cell, and cell–pathogen
interactions. The most common forms of sialic acid in animals are N-acetylneuraminic acid
(Neu5Ac) and its hydroxylated form, N-glycolylneuraminic acid (Neu5Gc) (Figure 2C). In all
mammals except humans, cytidine monophospho-N-acetylneuraminic acid hydroxylase
(CMAH) catalyzes the addition of an oxygen atom onto the methyl group of the acetyl group
of CMP-Neu5Ac to give Neu5Gc [89]. In humans, CMAH is inactivated by deletion of exon 6,
which would encode the hydroxylase active site. The relevant mutation occurred more than 0.5
million years ago, before the Neanderthal divergence [90,91]. In humans, Neu5Gc is detected at
low levels, likely derived from food intake [89]. The loss of catalytically active CMAH in humans is
proposed to be associated with the acquisition of either resistance or susceptibility to pathogens
that preferentially recognize Neu5Gc or Neu5Ac [92,93].
There is emerging evidence that the catalytically inactive human ‘CMAH-like’ protein has
biological roles. It is reported to be overproduced on the surface of adult stem cells and to
be involved in activation of Wnt signaling [91]. Overexpression of adult stem cell-speciﬁc CMAH
leads to an increased cellular uptake of exogenous Neu5Gc, suggesting a role for CMAH in
Neu5Gc transport [94]. CMAH is also proposed to be involved in glucose metabolism. CMAH–/–
knockout mice manifest an obese phenotype with impaired glucose tolerance and pancreatic b
cell dysfunction [95]. The absence of functional CMAH in humans is proposed to be involved in
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our susceptibility to progressive b cell degeneration and, thus, insulin resistance and type 2
diabetes mellitus [95].
From a biochemical perspective, the mechanism by which (nonhuman) CMAH catalyzes
hydroxylation of an unactivated acetyl methyl group is interesting but as yet no structure of
CMAH has been reported. Similar to ETHE1, CMAH is likely an oxygenase. However, unlike
ETHE1, which apparently only requires iron as cofactor, native murine CMAH activity is
stimulated by NADH, cytochrome b5, and NADH-cytochrome b5 reductase [96,97].
Group 3 hMBLf Enzymes: Summary
NAPE-PLD and CMAH have different biochemical mechanisms, further illustrating the diverse
capacities of the MBLf, although the phospholipase mechanism of NAPE-PLD is related to the
nuclease activities of the Group 2 enzymes. Both the two Group 3 hMBLf proteins likely have
pleiotropic roles in metabolism. From a medicinal perspective, the links between catalytically
inactive human CMAH and diabetes, and between NAPE-PLD and obesity/metabolic syn-
drome, are notable and are stimulating interest in medicinally targeting their respective path-
ways. In this regard, NAPE-PLD is of particular interest because of its key role in the
endocannabinoid pathway, which has multiple medicinal applications, including in regulation
of the anti-inﬂammatory response.
Concluding Remarks
The bacterial b-lactam antibiotics hydrolyzing MBL enzymes have a clear and, as far as we know,
simply executed role in antibiotic resistance; that is, they add water to b-lactam antibiotics,
thereby inactivating them. The available evidence suggests that, with appropriate effort, they will
be amenable to pharmaceutical inhibition. The biocatalytic roles of other MBLf enzymes range
from hydrolysis reactions (e.g., of thioesters, phospholipids, and nucleic acids, but notably not
as yet of peptides and/or proteins), to the more exotic redox chemistry of ETHE1 and CMAH.
Importantly, the mechanisms of hydrolysis-type MBLf enzymes are likely related to the well-
studies b-lactam antibiotics hydrolyzing MBLs. Thus, the relatively small hMBLf structural family
comprises a diverse set of 18 metallo-protein domains, many of which are known to have
important and emerging biological roles, including in DNA repair and/or resistance to anticancer
drugs (hMBLf nucleases SNM1A–C), regulation of expression (CPSF73), detoxiﬁcation (Glyox-
alase II and ETHE1), brain function (NAPE-PLD), and in metabolism (NAPE-PLD, CMAH) (see
Outstanding Questions). In several cases, mutations in the genes encoding hMBLf proteins can
have profound pathophysiological consequences. Some of the roles of hMBLf proteins are likely
pleiotropic and, at least in the cases of the nucleases (in particular RNA-processing enzymes),
the enzymes operate in conjunction with other domains and in dynamic multicomponent
complexes. These factors will complicate their prosecution as pharmaceutical targets. However,
the core domains of hMBLf proteins have conserved folds in their catalytic domains and, at least
at a superﬁcial level, as reveled by crystallographic analyses, unexpectedly similar active sites in
terms of metal-binding residues. The available structures provide a basis for inhibitor design, and
work with prokaryotic MBLs shows that the family is tractable for small-molecule inhibition. Thus,
the hMBLf family should be amenable to a template-based small-molecule probe approach for
use in dissecting functional aspects of the roles of hMBLf proteins in regulating expression and in
DNA repair, as well as pharmaceutical target validation. By analogy to work on the serine b-
lactamases, the development of inhibitors of hMBLf enzymes that are involved in resistance to
chemotherapeutic agents, such as cisplatin or mitomycin (e.g., SNM1 enzymes), may be of
particular medicinal interest.
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Outstanding Questions
What are the physiologically relevant
biochemical functions of the uncharac-
terized hMBLf enzymes?
What are the mechanisms of the
hMBLf enzymes catalyzing reactions,
such as that of ETHE1?
What metals are used by hMBLf
enzymes in cells?
What are the functions that regulate
hMBLf nucleases activity in the cleav-
age and polyadenylation speciﬁcity fac-
tor and integrator complexes?
How do the hMBLf nucleases achieve
selectivity in cells?
Are hMBLf enzymes tractable drug tar-
gets? For example, might targeting
them extend the use of cancer
chemotherapeutics forming interstrand
crosslinks?
Are MBLf proteins particularly well
suited to confer drug resistance? If
so, why?
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